Balance. Accordingly the main operations of the Company at present are business development and capital attraction. The Company has been in discussions with multiple strategic investors to fund internal product development, as well as with third parties who are interested in developing novel therapeutics that target the NETosis pathway. While these discussions have been encouraging, they have been tempered by the current macroeconomic trends that are impacting deal-making globally.
PAB Price at posting:
0.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)